Recombinant DNA Technology Market PPT: Demand, Trends and Business Opportunities 2023-28

1
Global Recombinant DNA Technology Market Research
and Forecast Report 2023-2028




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Recombinant DNA Technology Market Research
Report The latest report by IMARC, titled
Recombinant DNA Technology Market Global
Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2023-2028 " the global recombinant
DNA technology market reached a value of US
729.8 Billion in 2022. Recombinant
deoxyribonucleic acid (DNA) technology refers to
the process of altering genetic materials to
obtain desired characteristics in living
organisms or their products. It involves multiple
steps, such as isolation of genetic material,
restriction enzyme digestion, amplification using
polymerase chain reaction (PCR), ligation of DNA
molecules, and insertion of recombinant DNA into
the host. It is widely used in manufacturing
pharmaceuticals, novel enzymes for food
processing, production of genetically modified
organisms (GMO), gene therapy, and clinical
diagnosis. Recombinant DNA technology is vital in
improving health, enhancing food resources, and
solving environmental problems. It also aids in
the production of vaccines and protein therapies
such as human insulin, interferon, and human
growth hormone. Request Free Sample Report
https//www.imarcgroup.com/recombinant-dna-technol
ogy-market/requestsample
4
Report Description and Highlights
Report Description

Global Recombinant DNA Technology Market
Trends The global recombinant DNA technology
market is primarily being driven by its
increasing utilization in the pharmaceutical
industry. Recombinant DNA technology is
extensively used in developing vaccines and
manufacturing insulin, human growth hormones,
antibiotics, and monoclonal antibodies. In
addition, the widespread adoption of gene therapy
in the healthcare industry to treat cancer,
cardiovascular diseases (CVDs), infertility, and
genetic diseases is acting as another
growth-inducing factor. Furthermore, the
increasing demand for recombinant DNA technology
in the agriculture industry to develop GMO crops
with better yield, microbial resistance, drought
resistance, salt tolerance, and high nutrition
levels is providing an impetus to the market
growth. Additionally, the introduction of new
technologies, such as Clustered regularly
interspaced short palindromic repeats (CRISPR or
Cas9), Zinc-finger nucleases (ZFNs), and
transcription activator-like effector nucleases
(TALENs) for simple, cost-effective, and precise
genome editing is creating a positive outlook for
the market. Other factors, including increasing
demand for recombinant DNA technology for
improving different health conditions, extensive
research and development (RD) activities in
novel therapeutics, and widespread utilization in
the production of transgenic animals, are
anticipated to drive the market growth. On
account of the aforementioned factors, the market
value is expected to reach US 966.8 Billion by
2028, exhibiting a CAGR of 4.7 during
2023-2028. Looking forward, the market value is
projected to reach a strong growth during the
forecast period (2023-2028).
5
Report Description and Highlights
Report Description
Market Summary Breakup by Product Med
ical Therapeutic Agent
Human Protein Vaccines
Non-Medical Biotech Cr
ops Specialty Chemicals
Others Breakup by Component
Expression System Cloning Vector Breaku
p by Application Food and Agriculture
Health and Disease Environment

6
Report Description and Highlights
Report Description
Others Breakup by End User B
iotechnology and Pharmaceutical Companies
Academic and Government Research
Institutes Others Breakup by Region
North America United Sta
tes Canada Asia-Pacifi
c China Japan
India South Ko
rea Australia
Indonesia Others Europe

7
Report Description and Highlights
Report Description
Germany France
United Kingdom
Italy Spain
Russia Others Latin Am
erica Brazil M
exico Others Middle Ea
st and Africa

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• Amgen Inc Cibus F.Hoffmann-La Roche Ltd GenScript
  GlaxoSmithKline plc. Horizon Discovery Group plc M
  erck KGaA New England Biolabs Novo Nordisk A/S Pfi
  zer Inc. Sanofi S.A Syngene International Ltd (Bio
  con Limited)
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/recombinant-dna-technol
  ogy-market

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us